Manufacturing processes, scale-up, and production
BeiGene announced that BEQALZI™ (sonrotoclax) received accelerated approval from the U.S. FDA on May 13, 2026. This approval is for the treatment of adult patients with relapsed or refractory mantle c...
Biogen (BIIB) announced the completion of its acquisition of Apellis Pharmaceuticals on May 14, 2026. The acquisition was finalized following a successful tender offer where Biogen acquired approximat...
Ionis Pharmaceuticals announced positive topline results from its pivotal Phase 1-3 study of zilganersen for Alexander disease (AxD), a rare and often fatal neurological condition.
AbbVie announced an update to its 2026 earnings guidance in an 8-K filing on April 3, 2026. The update reflects a $744 million pre-tax charge for acquired IPR&D (In-Process Research and Development) a...
Moderna, Inc. announced in an 8-K filing that the FDA issued a Refusal-to-File (RTF) letter for its Biologics License Application (BLA) for mRNA-1010, its investigational seasonal influenza vaccine.
Regeneron Pharmaceuticals announced its fourth quarter and full year 2025 financial results, showcasing revenue growth driven by Dupixent and EYLEA HD. Q4 revenues increased 3% to $3.
Merck (MRK) reported its Q4 and full-year 2025 financial results, highlighting strong performance in oncology (driven by KEYTRUDA), animal health, and increasing contributions from newer products like...
Pfizer (PFE) released its Q4 and full-year 2025 financial results, reporting full-year revenues of $62.6 billion, a 2% operational decline year-over-year, although non-COVID product revenues grew 6%.